CorMedix Inc. reports results for the quarter ended June 30 - Earnings Summary

CorMedix

13/08/2026 14:31

CorMedix Inc. CRMD.OQ reported quarterly adjusted earnings of 32 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 28 cents.  The mean expectation of five analysts for the quarter was for earnings of 24 cents per share. Wall Street expected results to range from 17 cents to 31 cents per share.
Revenue rose 156.5% to $101.93 million from a year ago; analysts expected $95.62 million. 
CorMedix Inc.'s reported EPS for the quarter was 29 cents​.
The company reported quarterly net income of $25.99 million.
CorMedix Inc. shares had fallen by 9.6% this quarter and lost 39.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.2% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for CorMedix Inc. is $15.00, about 52.7% above its last closing price of $7.10
This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.24
0.32
Beat
Mar. 31 2026 
0.36
0.49
Beat
Dec. 31 2025 
0.82
0.16
Missed
Sep. 30 2025 
0.65
1.26
Beat